Septerna (SEPN) Share-based Compensation (2023 - 2026)
Septerna's quarterly Share-based Compensation came in at $6.0 million in Q1 2026, up 305.87% year-on-year from $1.5 million in Q1 2025, and up 126.47% quarter-over-quarter from $2.7 million in Q4 2025.
Septerna has reported Share-based Compensation for 4 years, with the latest figure at $6.0 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 305.87% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $13.0 million (up 220.66% YoY), and the FY2025 full-year result was $8.5 million, up 168.91% from the prior year.
- Share-based Compensation for Q1 2026 stood at $6.0 million, up from $2.7 million in the prior quarter.
- The five-year high for Share-based Compensation was $6.0 million in Q1 2026, with the low at $347000.0 in Q3 2023.
- Average Share-based Compensation over 4 years is $1.7 million, with a median of $1.3 million recorded in 2024.
- Year-over-year, Share-based Compensation jumped 96.83% in 2024 and soared 305.87% in 2026.
- Tracing SEPN's Share-based Compensation over 4 years: stood at $575000.0 in 2023, then jumped by 119.83% to $1.3 million in 2024, then soared by 110.13% to $2.7 million in 2025, then soared by 126.47% to $6.0 million in 2026.
- The last three Share-based Compensation figures came in at $6.0 million (Q1 2026), $2.7 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - | 6.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.02 Mn |
| Mar 31, 2026 | 6.02 Mn |
| Dec 31, 2025 | 2.66 Mn |
| Dec 31, 2025 | 2.66 Mn |
| Sep 30, 2025 | 2.53 Mn |
| Sep 30, 2025 | 2.53 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Mar 31, 2025 | 1.48 Mn |
| Mar 31, 2025 | 1.48 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | 683,000.00 |
| Sep 30, 2024 | 683,000.00 |
| Jun 30, 2024 | 628,000.00 |
| Jun 30, 2024 | 628,000.00 |
| Mar 31, 2024 | 577,000.00 |
| Mar 31, 2024 | 577,000.00 |
| Dec 31, 2023 | 575,000.00 |
| Dec 31, 2023 | 575,000.00 |
| Sep 30, 2023 | 347,000.00 |
| Sep 30, 2023 | 347,000.00 |